Malaria is still a complex and lethal parasitic infectious disease, despite the availability of effective antimalarial drugs. Resistance of malaria parasites to current treatments necessitates new antimalarials targeting proteins. The present study reported the design and synthesis of a series of a 2-(4-substituted piperazin-1-yl)--(5-((naphthalen-2-yloxy)methyl)-1,3,4-thiadiazol-2-yl)acetamide hybrids for the inhibition of dihydrofolate reductase (DHFR) using computational biology tools followed by chemical synthesis, structural characterization, and functional analysis.
View Article and Find Full Text PDF